While PSA is the primary marker for prostate cancer, in the mCRPC setting, circulating tumor cell (CTC) enumeration has emerged as a valuable prognostic and monitoring tool. The CellSearch system counts CTCs (EpCAM+, Cytokeratin+, CD45-) in blood. A high CTC count (e.g., ≥5 per 7.5 mL) is associated with poor prognosis. Changes in CTC count during treatment (e.g., conversion from unfavorable to favorable) can provide an early indication of treatment response or progression, sometimes before changes in PSA or imaging.

Break down complex topics into smaller, manageable chunks for easier recall.

Zambia

• Naomi Miselo – 31 pts

• Visual Pathway Lesions
• Positive and Negative Symptoms
• Hallucinations and Delusions
• Antipsychotic Medications
• Emergency: Environmental Emergencies